A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

Key facts

Study ID

NCT01766336

Run by

OPKO Health, Inc.

People needed

296

Starts

2013-01-01

Expected to finish

2015-08-01

Last updated by the study team

2019-10-21

Who can join

Age: 50 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Complete Week 12 visit of AG201
• Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests

You may not qualify if…

• Is currently using any other investigational or experimental drugs or devices
• Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study

Where it is running

• TransitionTIL Investigational Site — Birmingham, Alabama, United States
• TransitionTIL Investigational Site — Phoenix, Arizona, United States
• TransitionTIL Investigational Site — Phoenix, Arizona, United States
• TransitionTIL Investigational Site — Encino, California, United States
• TransitionTIL Investigational Site — Escondido, California, United States
• TransitionTIL Investigational Site — Fresno, California, United States
• TransitionTIL Investigational Site — Long Beach, California, United States
• TransitionTIL Investigational Site — Newport Beach, California, United States
• TransitionTIL Investigational Site — Orange, California, United States
• TransitionTIL Investigational Site — Norwalk, Connecticut, United States
• TransitionTIL Investigational Site — Washington D.C., District of Columbia, United States
• TransitionTIL Investigational Site — Atlantis, Florida, United States
• TransitionTIL Investigational Site — Deerfield Beach, Florida, United States
• TransitionTIL Investigational Site — Delray Beach, Florida, United States
• TransitionTIL Investigational Site — Lake Worth, Florida, United States
• TransitionTIL Investigational Site — Oakland Park, Florida, United States
• TransitionTIL Investigational Site — Orlando, Florida, United States
• TransitionTIL Investigational Site — Port Charlotte, Florida, United States
• TransitionTIL Investigational Site — Sarasota, Florida, United States
• TransitionTIL Investigational Site — Columbus, Georgia, United States
• TransitionTIL Investigational Site — Savannah, Georgia, United States
• TransitionTIL Investigational Site — Springfield, Illinois, United States
• TransitionTIL Investigational Site — Easton, Maryland, United States
• TransitionTIL Investigational Site — Winchester, Massachusetts, United States
• TransitionTIL Investigational Site — Saint Paul, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.